List of Tables
Table 1. Global Oral Medications for Multiple Sclerosis Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Oral Medications for Multiple Sclerosis Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Oral Medications for Multiple Sclerosis Market Competitive Situation by Manufacturers in 2024
Table 4. Global Oral Medications for Multiple Sclerosis Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Oral Medications for Multiple Sclerosis Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Oral Medications for Multiple Sclerosis Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Oral Medications for Multiple Sclerosis Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Oral Medications for Multiple Sclerosis, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Product Type & Application
Table 12. Global Key Manufacturers of Oral Medications for Multiple Sclerosis, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oral Medications for Multiple Sclerosis by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Medications for Multiple Sclerosis as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oral Medications for Multiple Sclerosis Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Oral Medications for Multiple Sclerosis Sales by Region (2020-2025) & (K Units)
Table 18. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2020-2025)
Table 19. Global Oral Medications for Multiple Sclerosis Sales by Region (2026-2031) & (K Units)
Table 20. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2026-2031)
Table 21. Global Oral Medications for Multiple Sclerosis Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2020-2025)
Table 23. Global Oral Medications for Multiple Sclerosis Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2026-2031)
Table 25. North America Oral Medications for Multiple Sclerosis Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Oral Medications for Multiple Sclerosis Sales by Country (2020-2025) & (K Units)
Table 27. North America Oral Medications for Multiple Sclerosis Sales by Country (2026-2031) & (K Units)
Table 28. North America Oral Medications for Multiple Sclerosis Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Oral Medications for Multiple Sclerosis Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Oral Medications for Multiple Sclerosis Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Oral Medications for Multiple Sclerosis Sales by Country (2020-2025) & (K Units)
Table 32. Europe Oral Medications for Multiple Sclerosis Sales by Country (2026-2031) & (K Units)
Table 33. Europe Oral Medications for Multiple Sclerosis Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Oral Medications for Multiple Sclerosis Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Oral Medications for Multiple Sclerosis Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Oral Medications for Multiple Sclerosis Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Oral Medications for Multiple Sclerosis Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Oral Medications for Multiple Sclerosis Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Oral Medications for Multiple Sclerosis Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Oral Medications for Multiple Sclerosis Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Oral Medications for Multiple Sclerosis Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Oral Medications for Multiple Sclerosis Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Oral Medications for Multiple Sclerosis Sales (K Units) by Type (2020-2025)
Table 51. Global Oral Medications for Multiple Sclerosis Sales (K Units) by Type (2026-2031)
Table 52. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2020-2025)
Table 53. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2026-2031)
Table 54. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2020-2025)
Table 57. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2026-2031)
Table 58. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Type (2020-2025)
Table 59. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Type (2026-2031)
Table 60. Global Oral Medications for Multiple Sclerosis Sales (K Units) by Application (2020-2025)
Table 61. Global Oral Medications for Multiple Sclerosis Sales (K Units) by Application (2026-2031)
Table 62. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2020-2025)
Table 63. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2026-2031)
Table 64. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2020-2025)
Table 67. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2026-2031)
Table 68. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Application (2020-2025)
Table 69. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Application (2026-2031)
Table 70. Janssen Company Information
Table 71. Janssen Description and Business Overview
Table 72. Janssen Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Janssen Oral Medications for Multiple Sclerosis Product
Table 74. Janssen Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Novartis Oral Medications for Multiple Sclerosis Product
Table 79. Novartis Recent Developments/Updates
Table 80. Sanofi Company Information
Table 81. Sanofi Description and Business Overview
Table 82. Sanofi Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Sanofi Oral Medications for Multiple Sclerosis Product
Table 84. Sanofi Recent Developments/Updates
Table 85. Biogen Company Information
Table 86. Biogen Description and Business Overview
Table 87. Biogen Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Biogen Oral Medications for Multiple Sclerosis Product
Table 89. Biogen Recent Developments/Updates
Table 90. Banner Life Sciences Company Information
Table 91. Banner Life Sciences Description and Business Overview
Table 92. Banner Life Sciences Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Banner Life Sciences Oral Medications for Multiple Sclerosis Product
Table 94. Banner Life Sciences Recent Developments/Updates
Table 95. Bristol Myers Squibb Company Information
Table 96. Bristol Myers Squibb Description and Business Overview
Table 97. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product
Table 99. Bristol Myers Squibb Recent Developments/Updates
Table 100. Merck Company Information
Table 101. Merck Description and Business Overview
Table 102. Merck Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Merck Oral Medications for Multiple Sclerosis Product
Table 104. Merck Recent Developments/Updates
Table 105. Qilu Pharmaceutical Company Information
Table 106. Qilu Pharmaceutical Description and Business Overview
Table 107. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product
Table 109. Qilu Pharmaceutical Recent Developments/Updates
Table 110. Sichuan Omnis Pharmaceutical Company Information
Table 111. Sichuan Omnis Pharmaceutical Description and Business Overview
Table 112. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product
Table 114. Sichuan Omnis Pharmaceutical Recent Developments/Updates
Table 115. HEC Pharm Company Information
Table 116. HEC Pharm Description and Business Overview
Table 117. HEC Pharm Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. HEC Pharm Oral Medications for Multiple Sclerosis Product
Table 119. HEC Pharm Recent Developments/Updates
Table 120. Cisen Pharmaceutical Company Information
Table 121. Cisen Pharmaceutical Description and Business Overview
Table 122. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product
Table 124. Cisen Pharmaceutical Recent Developments/Updates
Table 125. Nanjing Healthnice Pharmaceutical Company Information
Table 126. Nanjing Healthnice Pharmaceutical Description and Business Overview
Table 127. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product
Table 129. Nanjing Healthnice Pharmaceutical Recent Developments/Updates
Table 130. CGeneTech (Suzhou, China) Company Information
Table 131. CGeneTech (Suzhou, China) Description and Business Overview
Table 132. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product
Table 134. CGeneTech (Suzhou, China) Recent Developments/Updates
Table 135. Mylan Company Information
Table 136. Mylan Description and Business Overview
Table 137. Mylan Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Mylan Oral Medications for Multiple Sclerosis Product
Table 139. Mylan Recent Developments/Updates
Table 140. Zydus Company Information
Table 141. Zydus Description and Business Overview
Table 142. Zydus Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Zydus Oral Medications for Multiple Sclerosis Product
Table 144. Zydus Recent Developments/Updates
Table 145. Accord Healthcare Company Information
Table 146. Accord Healthcare Description and Business Overview
Table 147. Accord Healthcare Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. Accord Healthcare Oral Medications for Multiple Sclerosis Product
Table 149. Accord Healthcare Recent Developments/Updates
Table 150. Dr. Reddy's Laboratories Company Information
Table 151. Dr. Reddy's Laboratories Description and Business Overview
Table 152. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 153. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product
Table 154. Dr. Reddy's Laboratories Recent Developments/Updates
Table 155. Glenmark Pharmaceuticals Company Information
Table 156. Glenmark Pharmaceuticals Description and Business Overview
Table 157. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 158. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product
Table 159. Glenmark Pharmaceuticals Recent Developments/Updates
Table 160. Teva Company Information
Table 161. Teva Description and Business Overview
Table 162. Teva Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 163. Teva Oral Medications for Multiple Sclerosis Product
Table 164. Teva Recent Developments/Updates
Table 165. Sandoz Company Information
Table 166. Sandoz Description and Business Overview
Table 167. Sandoz Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 168. Sandoz Oral Medications for Multiple Sclerosis Product
Table 169. Sandoz Recent Developments/Updates
Table 170. Viatris Company Information
Table 171. Viatris Description and Business Overview
Table 172. Viatris Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 173. Viatris Oral Medications for Multiple Sclerosis Product
Table 174. Viatris Recent Developments/Updates
Table 175. Sun Pharmaceuticals Company Information
Table 176. Sun Pharmaceuticals Description and Business Overview
Table 177. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 178. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product
Table 179. Sun Pharmaceuticals Recent Developments/Updates
Table 180. Alembic Company Information
Table 181. Alembic Description and Business Overview
Table 182. Alembic Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 183. Alembic Oral Medications for Multiple Sclerosis Product
Table 184. Alembic Recent Developments/Updates
Table 185. Apotex Company Information
Table 186. Apotex Description and Business Overview
Table 187. Apotex Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 188. Apotex Oral Medications for Multiple Sclerosis Product
Table 189. Apotex Recent Developments/Updates
Table 190. Key Raw Materials Lists
Table 191. Raw Materials Key Suppliers Lists
Table 192. Oral Medications for Multiple Sclerosis Distributors List
Table 193. Oral Medications for Multiple Sclerosis Customers List
Table 194. Oral Medications for Multiple Sclerosis Market Trends
Table 195. Oral Medications for Multiple Sclerosis Market Drivers
Table 196. Oral Medications for Multiple Sclerosis Market Challenges
Table 197. Oral Medications for Multiple Sclerosis Market Restraints
Table 198. Research Programs/Design for This Report
Table 199. Key Data Information from Secondary Sources
Table 200. Key Data Information from Primary Sources
Table 201. Authors List of This Report
List of Figures
Figure 1. Product Picture of Oral Medications for Multiple Sclerosis
Figure 2. Global Oral Medications for Multiple Sclerosis Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Oral Medications for Multiple Sclerosis Market Share by Type: 2024 & 2031
Figure 4. Dimethyl Fumarate Product Picture
Figure 5. Fingolimod Product Picture
Figure 6. Teriflunomide Product Picture
Figure 7. Diroximel Fumarate Product Picture
Figure 8. Monomethyl Fumarate Product Picture
Figure 9. Siponimod Product Picture
Figure 10. Ozanimod Product Picture
Figure 11. Ponesimod Product Picture
Figure 12. Cladribine Product Picture
Figure 13. Global Oral Medications for Multiple Sclerosis Market Value by Application (2020-2031) & (US$ Million)
Figure 14. Global Oral Medications for Multiple Sclerosis Market Share by Application: 2024 & 2031
Figure 15. Hospital and Clinic
Figure 16. Retail Pharmacies
Figure 17. Other
Figure 18. Global Oral Medications for Multiple Sclerosis Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 19. Global Oral Medications for Multiple Sclerosis Market Size (2020-2031) & (US$ Million)
Figure 20. Global Oral Medications for Multiple Sclerosis Sales (2020-2031) & (K Units)
Figure 21. Global Oral Medications for Multiple Sclerosis Average Price (US$/Unit) & (2020-2031)
Figure 22. Oral Medications for Multiple Sclerosis Report Years Considered
Figure 23. Oral Medications for Multiple Sclerosis Sales Share by Manufacturers in 2024
Figure 24. Global Oral Medications for Multiple Sclerosis Revenue Share by Manufacturers in 2024
Figure 25. Global 5 and 10 Largest Oral Medications for Multiple Sclerosis Players: Market Share by Revenue in Oral Medications for Multiple Sclerosis in 2024
Figure 26. Oral Medications for Multiple Sclerosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 27. Global Oral Medications for Multiple Sclerosis Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 28. North America Oral Medications for Multiple Sclerosis Sales Market Share by Country (2020-2031)
Figure 29. North America Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2020-2031)
Figure 30. United States Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Canada Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Europe Oral Medications for Multiple Sclerosis Sales Market Share by Country (2020-2031)
Figure 33. Europe Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2020-2031)
Figure 34. Germany Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. France Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. U.K. Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Italy Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Russia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Asia Pacific Oral Medications for Multiple Sclerosis Sales Market Share by Region (2020-2031)
Figure 40. Asia Pacific Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2020-2031)
Figure 41. China Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Japan Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. South Korea Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. India Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Australia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. China Taiwan Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Southeast Asia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Latin America Oral Medications for Multiple Sclerosis Sales Market Share by Country (2020-2031)
Figure 49. Latin America Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2020-2031)
Figure 50. Mexico Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Brazil Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Argentina Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Colombia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Middle East and Africa Oral Medications for Multiple Sclerosis Sales Market Share by Country (2020-2031)
Figure 55. Middle East and Africa Oral Medications for Multiple Sclerosis Revenue Market Share by Country (2020-2031)
Figure 56. Turkey Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Saudi Arabia Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. UAE Oral Medications for Multiple Sclerosis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 59. Global Sales Market Share of Oral Medications for Multiple Sclerosis by Type (2020-2031)
Figure 60. Global Revenue Market Share of Oral Medications for Multiple Sclerosis by Type (2020-2031)
Figure 61. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Type (2020-2031)
Figure 62. Global Sales Market Share of Oral Medications for Multiple Sclerosis by Application (2020-2031)
Figure 63. Global Revenue Market Share of Oral Medications for Multiple Sclerosis by Application (2020-2031)
Figure 64. Global Oral Medications for Multiple Sclerosis Price (US$/Unit) by Application (2020-2031)
Figure 65. Oral Medications for Multiple Sclerosis Value Chain
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
